Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepB mAb19 in Chronic Hepatitis B
NCT05856890Phase 1Active, not recruiting
- Sponsor
- The Rockefeller University
- Start
- Apr 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of HepB mAb19 in Chronic Hepatitis B (CHB) (9 arms), sponsored by The Rockefeller University. Primary endpoints: Rate and severity of solicited adverse events at 2 weeks, Rate and severity of treatment-emerging unsolicited adverse events at 48 weeks and 12 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
HepB mAb19
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05856890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856890.